P
PhoreMost
A new-model drug discovery company based in Cambridge, UK
About PhoreMost
PhoreMost is a biotechnology company focused on expanding the druggable space through its innovative drug target identification platform. The company operates in the pharmaceutical and biotechnology markets, primarily serving clients involved in drug discovery and development. PhoreMost collaborates with leading organizations, such as Oxford Biomedica and XtalPi, to discover and develop next-generation therapies, including targeted protein degradation and gene therapy solutions. The business model revolves around partnerships and collaborations, leveraging its platform to identify first-in-class drug targets in areas of high unmet need, particularly in oncology and neurodegenerative disorders. PhoreMost generates revenue through research collaborations, licensing agreements, and milestone payments from its partners. The company is driven by a team of scientists and biotechnology professionals, led by an experienced management team passionate about advancing medical science.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Pampisford, United Kingdom
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 64.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, uk rio, Drug Development, Genetics and genomics, Spinout, Genome Engineering, Tech for Biotech and Pharma, uk is8 digital and technologies, uk is8 life sciences
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2024 | $12M | $230M | Amadeus Capital Partners · Astellas Venture · Parkwalk Advisors · Business Growth Fund | ↗ |
| SERIES BOther financing | Mar 2021 | $46M | $184M | Morningside · Astellas Venture · O2h Ventures · Business Growth Fund | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for PhoreMost is 160 monthly website visits, up 23.1% over the last three months. PhoreMost's team declined 2.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Jonathan Milner
Sunil Shah
Prashant Shah
Parkwalk Advisors
Amadeus Capital Partners
Series A8 investors entered at this stage
Cambridge Enterprise
5Y Capital
Business Growth Fund
Morningside
Astellas Venture
O2h Ventures
XtalPi- TGTrend Investment Group
Other known investors1 additional known investor
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PhoreMost on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PhoreMost’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.